This website collects cookies to deliver better user experience. Cookie Policy
Accept
Sign In
The Wall Street Publication
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Reading: Moderna Drops Pursuit of U.S. Patent for Key Component of Covid-19 Vaccine
Share
The Wall Street PublicationThe Wall Street Publication
Font ResizerAa
Search
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Have an existing account? Sign In
Follow US
© 2024 The Wall Street Publication. All Rights Reserved.
The Wall Street Publication > Blog > Business > Moderna Drops Pursuit of U.S. Patent for Key Component of Covid-19 Vaccine
Business

Moderna Drops Pursuit of U.S. Patent for Key Component of Covid-19 Vaccine

Editorial Board Published December 17, 2021
Share
Moderna Drops Pursuit of U.S. Patent for Key Component of Covid-19 Vaccine
SHARE

Moderna Inc. MRNA 4.53% has abandoned its application for a U.S. patent covering its Covid-19 vaccine that has been the subject of a heated dispute with the National Institutes of Health over the invention of a key component of the shot.

The Cambridge, Mass., company said Friday it dropped the patent application “to allow more time for discussions with the NIH” aimed at an amicable resolution.

At issue was credit for a key component of Moderna’s Covid-19 vaccine, among the most widely used in the world. Patent holders could seek a cut of the shot’s billions of dollars in sales, though NIH hasn’t said whether it is interested in royalties.

The dispute arose over Moderna’s application in 2020 to the U.S. Patent and Trademark Office for a patent claiming the invention of a genetic sequence incorporated into its vaccine to trigger an immune response against the coronavirus.


Newsletter Sign-up

Coronavirus Briefing and Health Weekly

Get a morning briefing about the coronavirus pandemic three times a week and a weekly Health newsletter when the crisis abates.


Moderna had collaborated with scientists from the National Institute of Allergy and Infectious Diseases, which is part of the NIH, on developing and testing the vaccine.

The NIH asked Moderna to add the names of three government vaccine researchers as co-inventors in the patent application, but Moderna denied the request, sparking the dispute.

The NIH said in November it wouldn’t give up its claim as co-inventor of the vaccine, and would defer to legal authorities on how to resolve the dispute.

Moderna said it still believes that its own scientists invented the genetic sequence at the heart of the patent in question. Moderna said it also acknowledges that the NIH feels equally strongly that its scientists should be listed as co-inventors for their contemporaneous work on the sequence.

NIH didn’t immediately have a comment.

The sequence in question uses the genetic material known as messenger RNA, which instructs the body’s cells to make a version of the spike protein found on the surface of the coronavirus and in turn triggers the immune response.

The patent office earlier this year notified Moderna that the patent would be allowed. The patent’s issuance was pending until Moderna dropped it.

Moderna said Friday that if the patent had been issued, it could have interfered with further discussions aimed at resolving the dispute with the NIH. The company said it also wanted to avoid further distractions as it responds to the emerging Omicron variant of the coronavirus.

Moderna said it notified the NIH of its decision on Dec. 10. Moderna has filed a separate type of application that could enable a patent to be issued at a later date, the company said.

Write to Peter Loftus at [email protected]

Covid-19 Vaccines

Copyright ©2021 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Appeared in the December 18, 2021, print edition as ‘Moderna Drops Pursuit of Patent.’

Contents
Newsletter Sign-upCoronavirus Briefing and Health WeeklyCovid-19 Vaccines
TAGGED:Business NewsPAIDWall Street Publication
Share This Article
Twitter Email Copy Link Print
Previous Article Liberal mayors reverse course on ‘defund the police’ as crime surges Liberal mayors reverse course on ‘defund the police’ as crime surges
Next Article Gene Lee, CEO of Olive Garden Parent, to Retire Gene Lee, CEO of Olive Garden Parent, to Retire

Editor's Pick

California dwelling of lacking child’s mother and father searched; father has served time for youngster cruelty

California dwelling of lacking child’s mother and father searched; father has served time for youngster cruelty

San Bernardino County sheriff’s investigators on Sunday, Aug. 17, searched the house of the mother and father of the infant…

By Editorial Board 9 Min Read
Farmer Needs a Spouse: John Sansone and Claire Dinette Break up!
Farmer Needs a Spouse: John Sansone and Claire Dinette Break up!

Studying Time: 2 minutes It's sadly over for one more actuality tv…

4 Min Read
Meri Brown Hints at “Accusations, Heartbreak” in Instagram Publish
Meri Brown Hints at “Accusations, Heartbreak” in Instagram Publish

Studying Time: 3 minutes Meri Brown seems to be going via it…

5 Min Read

Oponion

Personal sector added simply 37,000 jobs in Could, lowest in over 2 years, ADP says

Personal sector added simply 37,000 jobs in Could, lowest in over 2 years, ADP says

First Belief Advisors chief economist Brian Wesbury discusses the probabilities…

June 4, 2025

7 unimaginable Bay Space issues to do over Thanksgiving weekend

As the vacation season comes knockin,’…

November 28, 2024

20 Greatest Hats for Males – Should Have’s For Any Style in 2024

We independently consider all really useful…

October 28, 2024

Taiwan Company Plans Texas Chip Wafer Factory—if Congress Approves Incentives

WASHINGTON—A Taiwan-based company said it plans…

June 27, 2022

AOC weighs one other bid for highly effective Home committee as outdated guard exits

Rep. Alexandria Ocasio-Cortez of New York…

May 2, 2025

You Might Also Like

Thales Reinforces its Management in eSIM and IoT Connectivity with a ‘Ready to Use’ Licensed Resolution
Business

Thales Reinforces its Management in eSIM and IoT Connectivity with a ‘Ready to Use’ Licensed Resolution

At a time when billions of linked objects are reshaping industries, Thales has achieved a vital safety certification for its…

4 Min Read
Soracom IoT Platform Achieves SOC 2 Kind 2 Compliance for Safety, Availability, and Confidentiality
Business

Soracom IoT Platform Achieves SOC 2 Kind 2 Compliance for Safety, Availability, and Confidentiality

Soracom, Inc., right now introduced that it has efficiently achieved System and Group Controls (SOC) 2 Kind 2 compliance, reinforcing…

2 Min Read
Mobile IoT Module Shipments Grew 23% in Q1 2025 as US–China tensions affect vendor panorama
Business

Mobile IoT Module Shipments Grew 23% in Q1 2025 as US–China tensions affect vendor panorama

In brief Shipments of mobile IoT modules and chipsets grew 23% year-over-year in Q1 2025, based on IoT Analytics’ International…

20 Min Read
Prime 7 Visitor Posting Marketplaces to Purchase Visitor Posts That Drive Search engine optimization Outcomes
Business

Prime 7 Visitor Posting Marketplaces to Purchase Visitor Posts That Drive Search engine optimization Outcomes

Utilizing a visitor posting market helps you overlook all that like a nasty nightmare. However how do you discover probably…

14 Min Read
The Wall Street Publication

About Us

The Wall Street Publication, a distinguished part of the Enspirers News Group, stands as a beacon of excellence in journalism. Committed to delivering unfiltered global news, we pride ourselves on our trusted coverage of Politics, Business, Technology, and more.

Company

  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • WP Creative Group
  • Accessibility Statement

Contact

  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability

Term of Use

  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices

© 2024 The Wall Street Publication. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?